Trial Profile

COMBinATion Nivolumab and ASTX727 (decitabine and cedazuridine) for treatment of primary GlioBlastoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cedazuridine/decitabine (Primary) ; Nivolumab (Primary)
Indications Glioblastoma
Focus Adverse reactions
Acronyms COMBAT-GB

Most Recent Events

07 Mar 2024 Recruitment end date is 31 March 2026 ,according to ISRCTN: Current Controlled Trials record.
23 Jan 2024 New trial record
19 Jan 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com